McMahon Lab

The Importance of RAS Effectors 

Mutational activation of RAS genes is detected in approximately 25 percent of human cancers. However, to date, activated RAS oncoproteins remain intractable pharmacological targets. Research in the McMahon Lab focuses on the importance of RAS effectors, such as the RAF family of protein kinases and phosphoinositide 3’ (PI3’)-kinases in the aberrant physiology of cancer cells.

To do so, the lab employs genetically engineered mouse (GEM) models of human cancer, patient-derived xenografts (PDXs) and cultures of cancer cells in combination with various genetic or pharmacological to explore how signaling pathways contribute to cancer cell initiation, progression, and response to therapy.

McMahon Lab Translational Cancer Research Program

The McMahon lab’s translational cancer research program focuses on the mechanisms underlying the development of metastatic melanoma, lung, and thyroid cancer. Although these malignancies are derived from distinct cell types, they share a striking number of common genetic alterations especially activating mutations in KRAS, BRAF, PIK3CA, or CTNNB1 (b-catenin).

In addition, many of these tumors display alterations in tumor suppressors such as CDKN2A, PTEN or TP53. To do this, Dr. McMahon’s laboratory works with cultured human cancer-derived cells and with genetically engineered mouse models of human cancer. Such model systems have demonstrated considerable value in the design and evaluation of new diagnostic, prognostic, and therapeutic tools to treat patients with cancer.

News & Blog

4
Noted UCSF Scientist Joins Research Team at Huntsman Cancer Institute
Research
Apr 06, 2015

Noted UCSF Scientist Joins Research Team at Huntsman Cancer Institute

Huntsman Cancer Institute,

Martin McMahon, Ph.D., joins Huntsman Cancer Institute (HCI) at the University of Utah in August as Professor in the Department of Dermatology and HCI Senior Director of Pre-Clinical Translation. Professor McMahon is currently the Efim Guzik Distinguished Professor of Cancer Biology at the University of California, San Francisco and Assistant Director of Professional Education and Co-leader of the Helen Diller Family Comprehensive Cancer Center (HCFCCC) Developmental Therapeutics Program.... Read More